Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial

Abstract Background Cutaneous microcystic lymphatic malformations (CMLMs) are rare conditions in children and adults. They present as clusters of vesicles full of lymph and blood to various extents, inducing maceration, esthetic impairment, pain, and impaired quality of life. The treatment is challe...

詳細記述

書誌詳細

主要な著者:	Sophie Leducq, Agnès Caille, Sébastien Barbarot, Nathalie Bénéton, Didier Bessis, Olivia Boccara, Anne-Claire Bursztejn, Christine Chiaverini, Anne Dompmartin, Catherine Droitcourt, Valérie Gissot, Dominique Goga, Laurent Guibaud, Denis Herbreteau, Anne Le Touze, Christine Léauté-Labrèze, Gérard Lorette, Stéphanie Mallet, Ludovic Martin, Juliette Mazereeuw-Hautier, Alice Phan, Patrice Plantin, Isabelle Quéré, Pierre Vabres, Hélène Bourgoin, Bruno Giraudeau, Annabel Maruani, Groupe de Recherche de la Société Française de Dermatologie Pédiatrique
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2019-12-01
シリーズ:	Trials
主題:	Cutaneous microcystic lymphatic malformation Lymphangiectasia Sirolimus Rapamycin Topical rapamycin Mammalian target of rapamycin inhibitor
オンライン･アクセス:	https://doi.org/10.1186/s13063-019-3767-8
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!